Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q03591
UPID:
FHR1_HUMAN
Alternative names:
H factor-like protein 1; H36
Alternative UPACC:
Q03591; A8K465; Q3B774; Q9UJ17
Background:
Complement factor H-related protein 1 (CFHR1), also known as H factor-like protein 1 or H36, plays a crucial role in complement regulation. Its ability to form dimers enhances its affinity for tissue-bound complement fragments, positioning it as a competitive inhibitor against the physiological complement inhibitor CFH. Additionally, CFHR1's association with lipoproteins suggests a significant role in lipid metabolism.
Therapeutic significance:
The involvement of CFHR1 in atypical hemolytic uremic syndrome (aHUS), a genetic condition marked by renal failure and a higher mortality rate, underscores its therapeutic significance. Variants affecting CFHR1, including specific deletions, have been linked to an increased risk of aHUS, highlighting the protein's potential as a target for therapeutic intervention in complement-mediated diseases.